Pfizer Investigational Site
New Haven, Connecticut, 06511, United States
NCT Number: NCT01102673
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK) and preliminary food effect of PF-04991532 following single escalating oral doses in healthy adult subjects.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
New Haven, Connecticut, 06511, United States
Safety/Tolerability and PK
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
Placebo to match PF-04991532 will be provided
Time frame: 1 month
Time frame: 1 month
Pfizer
Industry
A Phase 1 Placebo-Controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Food Effect of Single Escalating Oral Doses of PF-04991532 in Healthy Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05014204
Diabetes, Diabetes Mellitus
Los Angeles, California, United States
View Trial DetailsNCT05260021
Diabetes Mellitus, Diabetes Mellitus, Type 2
Los Angeles, California, United States
View Trial DetailsNCT04809220
Diabetes Mellitus, Diabetes Mellitus, Type 2
Nagoya, Aichi-ken, Japan
View Trial DetailsNCT01301456
Diabetes Mellitus, Diabetes Mellitus, Type 2
Chula Vista, California, United States
View Trial Details